BioNotebook: Seven public company funding updates, including Dendreon debt debacle and three IPO filings
This article was originally published in Scrip
Executive Summary
Dendreon sank 34% to $1.40 per share on 12 August – a new low for the year – after the Provenge (sipuleucel-T) maker notified investors that it has no way to repay a massive, looming debt of more than $600m.